Zhejiang Runyang New Material Technology Co., Ltd.

Zhejiang Runyang New Material Technology Co., Ltd. specializes in the development, manufacturing, and distribution of polyolefin foam materials, serving both domestic Chinese and international markets. The company's core offering is electron irradiation cross-linked polyethylene (IXPE), which is available in various grades, including antibacterial-enhanced, popular general-purpose, and specialized versions. These high-performance IXPE materials function as fundamental components across a broad spectrum of industries. Their applications span home building and interior decoration, automotive parts, baby care products, sports and leisure equipment, consumer electronics, household appliances, and medical devices, among others. Established in 2012, Zhejiang Runyang is headquartered in Hangzhou, China.

Zhejiang Runyang New Material Technology Co., Ltd. trades as 300920.SZ on SHZ. The company is classified in Basic Materials / Chemicals and reports in CNY.

The current profile places the business in Chemicals. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Zhejiang Runyang New Material Technology Co., Ltd. can be compared against peers such as Shandong Fengyuan Chemical Co., Ltd., Guangdong Yussen Energy Technology Co., Ltd., Henan Jindan Lactic Acid Technology Co., Ltd, Rastar Environmental Protection Materials Co.,Ltd., Hubei Xiangyuan New Material Technology Inc., Guangdong Kitech New Material Holding Co.,Ltd..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $4.09B, beta of 0.62, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

300920.SZ currently shows total debt of N/A and beta of 0.62. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.zj-runyang.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.